Scientific article
Open access

The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT

Published inBone marrow transplantation, vol. 49, no. 1, p. 55-61
Publication date2014

Several T-cell depletion (TCD) techniques are used for haploidentical hematopoietic SCT (HSCT), but direct comparisons are rare. We therefore studied the effect of in vitro TCD with graft engineering (CD34 selection or CD3/CD19 depletion, 74%) or in vivo TCD using alemtuzumab (26%) on outcome, immune reconstitution and infections after haploidentical HSCT. We performed a retrospective multicenter analysis of 72 haploidentical HSCT in Switzerland. Sixty-seven patients (93%) had neutrophil engraftment. The 1-year OS, TRM and relapse incidence were 48 (36-60)%, 20 (11-33)% and 42 (31-57)%, respectively, without differences among the TCD groups. In vivo TCD caused more profound lymphocyte suppression early after HSCT, whereas immune recovery beyond the second month was comparable between the two groups. Despite anti-infective prophylaxis, most patients experienced post-transplant infectious complications (94%). Patients with in vivo TCD had a higher incidence of CMV reactivations (54% vs 28%, P=0.015), but this did not result in a higher TRM. In conclusion, TCD by graft engineering or alemtuzumab are equally effective for haploidentical HSCT.

Citation (ISO format)
MAREK, A et al. The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. In: Bone marrow transplantation, 2014, vol. 49, n° 1, p. 55–61. doi: 10.1038/bmt.2013.132
Main files (1)
Article (Published version)
ISSN of the journal0268-3369

Technical informations

Creation05/31/2014 5:56:00 PM
First validation05/31/2014 5:56:00 PM
Update time03/14/2023 9:17:33 PM
Status update03/14/2023 9:17:32 PM
Last indexation01/16/2024 10:49:29 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack